close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Cassava Sciences, Inc.

< Previous 1 2 Next >
News headline image
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Redemption Date Announced for Warrants
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Announces Dividend Distribution of Warrants to Shareholders
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Appoints Three New Members to its Board of Directors
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Completes Enrollment for Pivotal Phase 3 Program of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
MRI Data Suggest Simufilam is Not Associated with Amyloid-related Imaging Abnormalities (ARIA)
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences to Present at the Jefferies Biotech CNS/Neuro Summit in NY
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Invited to Present in Four Upcoming Investor Conferences
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Oral Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
New Research Shows Simufilam Suppresses Overactive mTOR
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
New Publication Highlights Basic Science Supporting Simufilam
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences to Present at the Jefferies Global Healthcare Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
News headline image
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Tickers SAVA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today